Global Impact

Global Impact

Subscribe

Third consecutive recognition for Novartis in Canada as a Great Place to Work®

Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz® (adalimumab)

Sandoz Canada launches the first generic versions of two original drugs: PrSandoz® Posaconazole and PrSandoz® Silodosin

2021 Top Employer Canada

London Drugs Award 2020

Biosimilars reimbursement update

Illustration: Coronavirus (Centers for Disease Control and Prevention)

Coronavirus

Biosimilars switch policies update: British Columbia expands its Biosimilars Initiative to include rituximab

Novartis in Canada, including Sandoz Canada, initiates Community Strong COVID-19 response program